Skip to content

The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China

The real world study of Eculizumab for paroxysmal nocturnal hemoglobinuria treatment in China

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2300067949
Enrollment
Unknown
Registered
2023-02-01
Start date
2023-02-01
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

paroxysmal nocturnal hemoglobinuria

Interventions

experimental group:Eculizumab

Sponsors

West China Hospitai,Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1. Age>= 18years. 2. Flow cytometry evaluation of PNH clone size>=10%. 3. LDH level>=2×ULN. 4. Hb=30mL/min.

Exclusion criteria

Exclusion criteria: 1. Current or previous treatment with a complement inhibitor. 2. History of N.meningitidis infection within 6 months prior to screening and up to first drug administration. 3. Hereditary complement deficiency. 4. HIV infection. 5. Active systemic bacterial, viral, or fungal infection within 14 days before first drug administration. 6. Immunized with a live attenuated vaccine within 1 month before first drug administration. 7. History of malignancy within 5 years prior to screening and up to the first drug administration. 8. History of myelodysplastic syndrome with Revised International Prognostic Scoring System (IPSS-R) prognostic risk categories of intermediate, high, and very high. 9. History of hypersensitivity, allergic, or anaphylactic reactions to any ingredient contained in eculizumab, including hypersensitivity to human,humanized,or murine monoclonal antibodies or known hypersensitivity to any constituent of the product. 10. Concurrent disease, treatment, procedure or surgery, or abnormality in clinical laboratory tests that could interfere with the conduct of the study, may pose any additional risk for the patient, or would, in the opinion of the investigator, preclude the patients safe participation in and completion of the study.

Design outcomes

Primary

MeasureTime frame
Mean proportion of patients with hemolysis control;The proportion of patients who achieve transfusion avoidance;

Secondary

MeasureTime frame
Proportion of patients with Breakthrough hemolysis;Proportion of patients with stabilized hemoglobin;Mean change in fatigue as assessed through the use of the FACIT-Fatigue;

Countries

China

Contacts

Public ContactChuan He

West China Hospitai,Sichuan University

chuanhhx@163.com+86 18980601252

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026